Clinical trial
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
NCT01670500
Study timeline
Study start (unknown)2012-10-01Date precision: month
Registry last updated2026-05-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
CisplatinDRUG · verified · RxNorm: cisplatin
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
DoxorubicinDRUG · verified · RxNorm: doxorubicin
Sponsors & collaborators
Beth Israel Deaconess Medical Centerlead sponsor
Dana-Farber Cancer Institutecollaborator
Mapped research locations
BostonMassachusetts, United States3Washington D.C.District of Columbia, United States2HoustonTexas, United States1BaltimoreMaryland, United States1DurhamNorth Carolina, United States1AuroraColorado, United States1New HavenConnecticut, United States1ProvidenceRhode Island, United States1New BrunswickNew Jersey, United States1HartfordConnecticut, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01670500 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.